Welcome to our dedicated page for Oculis Holding Ordinary shares news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding Ordinary shares stock.
Oculis Holding AG (Nasdaq: OCS) is a leading global biopharmaceutical company dedicated to saving sight and enhancing eye care. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is at the forefront of developing innovative treatments for serious eye diseases. The company's pipeline includes several promising candidates:
- OCS-01: A topical eye drop for diabetic macular edema (DME) and post-cataract surgery inflammation and pain. OCS-01 has shown compelling Phase 3 data, making it a potential new standard of care for these conditions.
- OCS-02: A topical biologic anti-TNFα eye drop for dry eye disease (DED) and non-infectious anterior uveitis. The OCS-02 RELIEF trial is in Phase 2b, with results eagerly anticipated.
- OCS-05: A neuroprotective candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma and diabetic retinopathy. The ACUITY trial is set to provide critical data by the end of the year.
Oculis recently announced its fourth-quarter and full-year 2023 financial results, highlighted by positive Phase 3 data for OCS-01 and the commencement of three clinical trials, including OCS-02's RELIEF trial. The company is on track for a catalyst-rich 2024 with significant upcoming milestones, including readouts from the RELIEF trial in Q2 and the OPTIMIZE-2 and ACUITY trials in Q4. These milestones are crucial for Oculis' plan to submit its first New Drug Application (NDA).
Under the leadership of CEO Riad Sherif, M.D., Oculis has achieved remarkable progress and continues to advance its diversified pipeline. The company is backed by leading international healthcare investors and boasts a seasoned management team with a strong track record of success.
Financially, Oculis has reported significant strides, supported by both new and existing investors. The company has dual listings on Nasdaq in the U.S. and Iceland, reflecting its robust financial health and market confidence.
For more information, please visit Oculis Holding AG's website. For investor and media inquiries, contact Ms. Sylvia Cheung, CFO at sylvia.cheung@oculis.com or Corey Davis, Ph.D. at LifeSci Advisors at cdavis@lifesciadvisors.com.
Oculis reported its Q1 2024 financial results and provided updates on its clinical programs, including the initiation of the second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema and completion of enrollment in OCS-02 Phase 2b RELIEF trial in Dry Eye Disease. The company raised $59 million in a direct equity offering, listed on Nasdaq Iceland Main Market, and strengthened its executive team. Financially, Oculis had a cash position of CHF 79.9 million, with research and development expenses of CHF 10.9 million. The company reported a net loss of CHF 16.1 million for Q1 2024. Oculis is on track with its clinical milestones, with topline results anticipated in the second and fourth quarters of 2024.
Oculis has completed enrollment in the Phase 2 ACUITY trial for OCS-05 in patients with Acute Optic Neuritis, with topline results expected in Q4 2024. The drug has received orphan drug designation in the US and Europe for AON. The trial aims to assess the safety and tolerability of OCS-05, offering potential neuroprotective benefits in ophthalmic diseases.
Oculis Holding AG has published an invitation to its 2024 Annual General Meeting, scheduled for May 29, 2024, in Zug, Switzerland. The meeting details and materials are available on the company's website.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) announced that its management will be presenting at the Bank of America Healthcare Conference in Las Vegas on May 14-16, 2024. Riad Sherif, M.D., the CEO, will deliver a company presentation on May 15th at 11:20 am PT. Interested investors can schedule one-on-one meetings through their Bank of America representative.
Oculis Holding AG has published an invitation to its 2024 Annual General Meeting to be held on May 29, 2024, in Zug, Switzerland. The meeting details and materials are available on the company's website.
FAQ
What is the current stock price of Oculis Holding Ordinary shares (OCS)?
What is the market cap of Oculis Holding Ordinary shares (OCS)?
What is Oculis Holding AG?
What products are in Oculis' pipeline?
Where is Oculis headquartered?
What recent achievements has Oculis made?
Who leads Oculis Holding AG?
What are the upcoming milestones for Oculis in 2024?
How did Oculis perform financially in 2023?
What conditions does OCS-01 treat?
What is the OCS-02 RELIEF trial?
How can I contact Oculis for investor or media inquiries?
